1/2-Collaborative Study: Testosterone Antidepressant Augmentation in Women

描述（由申请人提供）：重度抑郁症是一个重大的公共卫生问题，不成比例地影响妇女。大约70%的患者对标准SSRI治疗没有反应或仅部分反应，尽管剂量足够。在我们的开放标签试点数据中，三分之二对抗抑郁药耐药或部分耐药的重度抑郁症女性对极低剂量的生理性经皮睾酮给药有反应;三分之一接受治疗的女性在治疗8周后缓解，无高雄激素副作用。我们建议进行一项协作、随机、安慰剂对照试验，以确定是否需要进行更大规模的多中心试验 研究低剂量睾酮是否是一种有效的和耐受性良好的增强策略，在女性重度抑郁症和SSRI部分/无反应。我们建议从两个学术医学中心进行协作，多学科研究，以增加样本量，加速招募和增加样本多样性。

DESCRIPTION (provided by applicant): Major depressive disorder is a significant public health problem, disproportionately affecting women. Approximately 70% of patients do not respond or only partially respond to standard SSRI treatment despite adequate dosing. In our open-label pilot data, two-thirds of women with major depressive disorder who were resistant or partially resistant to antidepressants achieved a response to very low-dose, physiologic transdermal testosterone administration; one-third of women treated achieved remission after 8 weeks of therapy, with no hyperandrogenic side effects. We propose a collaborative, randomized, placebo-controlled trial to determine whether larger, multi-center trials are indicated to investigate whether low-dose testosterone is an efficacious and well-tolerated augmentation strategy in women with major depressive disorder and SSRI partial/nonresponse. We propose a collaborative, multidisciplinary study from two academic medical centers in order to increase sample size, accelerate recruitment and increase sample diversity.